{"id":21522,"date":"2022-04-04T05:07:00","date_gmt":"2022-04-03T21:07:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=21522"},"modified":"2022-04-05T22:01:06","modified_gmt":"2022-04-05T14:01:06","slug":"lancet%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9arad26-rad5%ef%bc%88%e4%bf%84%e7%bd%97%e6%96%af%e5%8d%ab%e6%98%9fv%ef%bc%89%ef%bc%8cchadox1-ncov-19%ef%bc%88%e7%89%9b%e6%b4%a5-%e9%98%bf%e6%96%af","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=21522","title":{"rendered":"[Lancet\u53d1\u8868\u8bba\u6587]\uff1arAd26-rAd5\uff08\u4fc4\u7f57\u65af\u536b\u661fV\uff09\uff0cChAdOx1 nCoV-19\uff08\u725b\u6d25-\u963f\u65af\u5229\u5eb7\uff09\u548cBBiBP-CorV\uff08\u4e2d\u56fd\u751f\u7269\uff09\u75ab\u82d7\u5bf960\u5c81\u4ee5\u4e0a\u963f\u6839\u5ef7\u4eba\u65b0\u51a0\u75c5\u6bd2\u611f\u67d3\u53ca\u6b7b\u4ea1\u98ce\u9669\u7684\u6548\u679c"},"content":{"rendered":"\n

ARTICLES| VOLUME 399, ISSUE 10331<\/a>, P1254-1264, MARCH 26, 2022<\/p>\n\n\n\n

Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study<\/h1>\n\n\n\n

Anal\u00eda Rearte, Juan Manuel Castelli, Ramiro Rearte,\u00a0et al<\/h3>\n\n\n\n

Lancet 2022; 399: 1254-1264<\/h3>\n\n\n\n

Summary<\/h2>\n\n\n\n

Background<\/h3>\n\n\n\n

In January, 2021, a vaccination campaign against COVID-19 was initiated with the rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines in Argentina. The objective of this study was to estimate vaccine effectiveness at reducing risk of SARS-CoV-2 infection and COVID-19 deaths in people older than 60 years.<\/p>\n\n\n\n

Methods<\/h3>\n\n\n\n

In this test-negative, case-control, and retrospective longitudinal study done in Argentina, we evaluated the effectiveness of three vaccines (rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV) on SARS-CoV-2 infection and risk of death in people with RT-PCR confirmed COVID-19, using data from the National Surveillance System (SNVS 2.0). All individuals aged 60 years or older reported to SNVS 2.0 as being suspected to have COVID-19 who had disease status confirmed with RT-PCR were included in the study. Unvaccinated individuals could participate in any of the analyses. People with suspected COVID-19 who developed symptoms before the start of the implementation of the vaccination programme for their age group or district were excluded from the study. The odds ratio of SARS-CoV-2 infection was evaluated by logistic regression and the risk of death in individuals with RT-PCR confirmed COVID-19 was evaluated by proportional hazard regression models, adjusted for possible confounders: age at the time of the symptom onset date, sex, district of residence, epidemiological week corresponding to the symptom onset date, and history of COVID-19. The estimation of vaccine effectiveness to prevent death due to COVID-19 was done indirectly by combining infection and death estimates. In addition, we evaluated the effect of the first dose of viral vector vaccines across time.<\/p>\n\n\n\n

Findings<\/h3>\n\n\n\n

From Jan 31, to Sept 14, 2021, 1\u2008282\u2008928 individuals were included, of whom 687\u2008167 (53\u00b76%) were in the rAd26-rAd5 analysis, 358\u2008431 (27\u00b76%) in the ChAdOx1 nCoV-19 analysis, and 237\u2008330 (18\u00b75%) in the BBIBP-CorV analysis. Vaccine effectiveness after two doses was high for all three vaccines, adjusted odds ratio 0\u00b736 (95% CI 0\u00b735\u20130\u00b737) for rAd26-rAd5, 0\u00b732 (0\u00b731\u20130\u00b733) for ChAdOx1 nCoV-19, and 0\u00b756 (0\u00b755\u20130\u00b758) for BBIBP-CorV. After two doses, the effect on deaths was higher than that on risk of infection: adjusted hazard ratio 0\u00b719 (95% CI 0\u00b718\u20130\u00b721) for rAd26-rAd5, 0\u00b720 (0\u00b718\u20130\u00b722) for ChAdOx1 nCoV-19, and 0\u00b727 (0\u00b725\u20130\u00b729) for BBIBP-CorV. The indirectly estimated effectiveness on deaths was 93\u00b71% (95% CI 92\u00b76\u201393\u00b75) for rAd26-rAd5, 93\u00b77% (93\u00b72\u201394\u00b73) for ChAdOx1 nCoV-19, and 85\u00b70% (84\u00b70\u201386\u00b70) for BBIBP-CorV following two doses. First dose effect of viral vector vaccines remained stable over time.<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n
\"\"\/<\/figure>\n\n\n\n

Interpretation<\/h3>\n\n\n\n

The vaccines used in Argentina showed effectiveness in reducing infection and death by SARS-CoV-2 and COVID-19.<\/p>\n\n\n\n

Funding<\/h3>\n\n\n\n

None.<\/p>\n","protected":false},"excerpt":{"rendered":"

ARTICLES| VOLUME 399, ISSUE 10331, P1254-1264 […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/21522"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21522"}],"version-history":[{"count":2,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/21522\/revisions"}],"predecessor-version":[{"id":21631,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/21522\/revisions\/21631"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21522"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}